论文部分内容阅读
目的:探讨选择聚乙二醇干扰素(PEG-IFN-α)对慢性乙型肝炎(CHB)患者治疗后获得的临床疗效以及对骨髓抑制产生的影响。方法:选取我院2014年01月-2016年01月收治的CHB患者120例作为研究对象。所有患者均符合2010年慢性乙型肝炎诊断标准。根据临床不同的治疗方法实施随机分组,其中A组60例,选择PEG-IFN-α-2b或PEG-IFN-α-2a注射液进行治疗,B组60例,选择普通IFNα注射液进行治疗,分别检测治疗第12、24、48周时的HBV-DNA水平、白细胞计数(WBC)、PLT(血小板)及中性粒细胞(NEU)计数。结果:在HBV-DNA水平方面,A组治疗效果明显优于B组(P<0.05),WBC、PLT及NEU方面:A组下降小于B组(P<0.05)。结论:针对CHB患者,临床选择PEG-IFN-α制剂进行治疗,不仅能够提高HBV-DNA治疗效果,同时可减少患者骨髓抑制现象,最终发挥显著的临床治疗效果。
Objective: To investigate the clinical efficacy of pegylated interferon (PEG-IFN-α) in the treatment of patients with chronic hepatitis B (CHB) and its effect on bone marrow suppression. Methods: A total of 120 CHB patients admitted to our hospital from January 2014 to January 2016 were selected as the study subjects. All patients were in line with the 2010 chronic hepatitis B diagnostic criteria. According to the clinical different treatment methods were randomly divided into groups, including 60 cases in group A, the choice of PEG-IFN-α-2b or PEG-IFN-α-2a injection for treatment, B group of 60 patients, the choice of normal IFNα injection for treatment, The levels of HBV-DNA, WBC, PLT and neutrophil count (NEU) were detected at the 12th, 24th and 48th week respectively. Results: In the aspect of HBV-DNA level, the treatment effect of group A was better than that of group B (P <0.05). In WBC, PLT and NEU group, the decrease in group A was less than that in group B (P <0.05). CONCLUSIONS: In the patients with CHB, the clinical choice of PEG-IFN-α preparation can not only improve the therapeutic effect of HBV-DNA, but also reduce the bone marrow suppression in patients with CHB, and finally exert a significant clinical therapeutic effect.